A new resource on optimal management of injectable medicines for Australians with COVID-19 disease has been released
The resource was launched by the Society of Hospital Pharmacists of Australia as part of an update to its Australian Injectable Drugs Handbook this week.
The new section of the ‘yellow book’, now live through online suppliers and via the SHPA website, lists how key medicines and important medical equipment can be managed or prioritised as part of Australia’s preparations and national response to COVID-19.
SHPA President Peter Fowler says the new AIDH8 COVID-19 resource supports excellent medicines safety in the event of a surge in cases in Australian hospitals.
“Informed by the experiences of hospital pharmacists overseas SHPA has added compatibility information for medicines likely to be used in the management of COVID-19 patients in intensive care units, resources to assist with planning in the event of an infusion pump shortage, a quick guide to identifying medicines that may be given by IV injection and a list of highest priority medicines for administration via an infusion pump,” he said.
“As with every monograph in AIDH8, we are ensuring the latest knowledge is made available to as many hospitals pharmacists and their colleagues as possible, to uphold safe medicines practice in this uncertain time.”
SHPA Chief Executive Kristin Michaels says the update to AIDH8 comes at a critical time for medicines safety in Australia.
“With the relaxing of restrictions across all states and territories, it is important to remember that while the immediate threat of coronavirus has eased, it has not abated.
‘We will continue to see community transmission, outbreaks of case clusters and, unfortunately, COVID-19 related hospitalisations.
“By including new guidance specific to COVID-19 care, SHPA is ensuring our indispensable AIDH resource continues to provide up-to-date and relevant information for health professionals, ensuring the safe and quality use of medicines in all care settings across Australia.”